1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Tong Ren Tang Technologies Co. Ltd.

Tong Ren Tang Technologies Co. Ltd.

TGRNF
Tong Ren Tang Technologies Co. Ltd.US flagOther OTC
0.49
USD
- -
- -
633.86MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
2.41
2.61
3.18
3.64
3.92
3.95
3.5
3.6
4.22
4.68
5.29
5.67
- -
Basic EPS, GAAP
0.32
0.36
0.42
0.47
0.52
0.53
0.33
0.37
0.4
0.46
0.46
0.41
- -
Free Cash Flow per Basic Share
0.15
0.04
0.1
-0.02
0.2
0.48
0.61
-0.26
0.68
0.44
0.35
-0.12
- -
Dividend per Share
0.12
0.12
0.14
0.15
0.16
0.17
0.18
0.16
0.16
0.16
0.16
0.18
- -
Book Value per Share
0.66
1.14
2.27
2.54
1
1
1
1
3.66
3.92
4.18
4.38
- -
Tangible Book Value per Share
3.31
3.46
3.98
4.53
4.98
5.62
5.74
6.01
6.32
6.99
7.49
7.88
- -
Basic Weighted Avg Shares
1,209
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
- -
Sales/Revenue/Turnover
2,911
3,341
4,067
4,665
5,025
5,060
4,476
4,607
5,400
5,992
6,773
7,260
6,484
Operating Margin (%)
21.13
21.3
21.68
21.59
23.21
23.66
20.96
20.96
19.9
20.03
16.73
13.57
12.37
Depreciation Expense
47
61
75
79
85
88
160
270
250
262
277
290
334
Net Income, GAAP
390
462
541
596
667
678
418
468
507
583
590
522
396
Effective Tax Rate (%)
15.45
16.78
17.47
16.86
16.83
16.67
19.72
16.3
17.05
17.36
14.64
16.42
19.67
Profit Margin (%)
13.4
13.83
13.3
12.77
13.27
13.4
9.33
10.15
9.39
9.73
8.71
7.19
6.11
Working Capital
3,291
3,415
3,912
5,172
5,442
5,899
5,891
4,999
5,672
7,021
7,820
7,992
8,411
LT Debt
39
- -
- -
918
915
911
1,283
578
819
1,296
1,476
1,283
1,545
Total Equity
4,009
4,436
5,163
5,885
6,460
7,277
7,415
7,752
8,158
9,017
9,652
10,165
10,265
Return on Invested Capital (%)
15.85
13.53
14.64
13.45
13.21
12.41
8.63
8.75
9.2
9.57
8.72
6.85
5.14
Return on Capital (%)
19.72
14.84
10.16
6.89
7.69
8.62
2.82
3.99
2.95
2.36
2.44
2.03
1.66
Return on Common Equity (%)
50.81
40.89
24.81
19.34
29.38
52.92
32.61
36.51
16.98
12
11.38
9.52
6.98

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.19%
5.82%
0.98%
Free Cash Flow
-273.07%
-312.62%
-1,011.73%
Net Income, GAAP
-1.37%
-2.2%
-24.06%
Sales/Revenue/Turnover
5.22%
7.54%
-10.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
6,773
2024
- -
- -
- -
- -
7,260
2025
- -
- -
- -
- -
6,484

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.46
2024
- -
- -
- -
- -
0.41
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.16
2024
- -
- -
- -
- -
0.18
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Yi Zhang
Full Time Employees
3,991
Sector
Healthcare
Industry
Drug Manufacturers - General
Address
No. 20 Nansanhuan Zhonglu Road Beijing People's Republic of China 100079
IPO Date
Aug 17, 2012
Website
tongrentangkj.com
Similar Companies
Daiichi Sankyo Company, Limited (DSNKY)
Chugai Pharmaceutical Co., Ltd. (CHGCY)
AbbVie Inc. (ABBV.BA)
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
Eli Lilly and Company (LLY.SW)
Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
Business
Tong Ren Tang Technologies Co. Ltd. Tong Ren Tang Technologies Co. Ltd. (TGRNF) manufactures and sells traditional Chinese medicine products, including prescription medicines, herbal dietary supplements, granules, pills, decoction pieces, ointments, tea drinks, foot care products, biological products, Chinese and Western medicines, cosmetics, healthcare products, biochemical products, plant extracts, food, and daily chemical products; cultivates, purchases, and sells Chinese medicinal raw materials; provides medical research and development, advertisement, Chinese medical consultation and treatment services, internal and external surgery, medical examinations, hospital management, and wholesale and retail of medicines and healthcare items in Mainland China and Hong Kong. Founded in 1669 and headquartered in Beijing, China, the company operates through segments focused on pharmaceutical manufacturing, retail, and research and development of traditional Chinese medicine, targeting consumers seeking herbal remedies, health supplements, and topical medicines with approximately 3,991 employees. Recent developments include ongoing expansion through its affiliate Tong Ren Tang Healthcare Investment Co. Ltd., which acquired 65% equity in Sanxi Tang Health Hospital and Sanxi Tang Traditional Chinese Medicine Shop in 2022, 70% of Shanghai Chengzhitang and 60% of Shanghai Zhonghetang in 2024, and additional institutions such as Anshan Tong Ren Tang Chinese Medicine Hospital and Shijiazhuang Tong Ren Tang Chinese Medicine Hospital, driving revenue growth in medical services and positioning for further acquisitions of up to five profitable medical institutions by 2029 in regions including Beijing, the Yangtze River Delta, Central China, and the Greater Bay Area.